Quantron

QUANTRO Therapeutics is a Vienna-based biotechnology company dedicated to discovering and developing novel small molecule therapeutics that target disease-causing transcriptional programs. The company’s core technology, "Transcriptional Fingerprinting," integrates time-resolved RNA sequencing with metabolic labeling to identify drug candidates that can modulate transcription factors, a class of targets traditionally considered "undruggable." QUANTRO’s primary focus is on oncology, with a lead program targeting the MYC proto-oncogene, a master regulator of cancer cell growth. As a spin-off from the Institute of Molecular Biotechnology (IMBA) and the Research Institute of Molecular Pathology (IMP), the company leverages world-class expertise in functional genetics and transcriptomics. QUANTRO has established significant partnerships with industry leaders such as Boehringer Ingelheim and Evotec to accelerate its drug discovery efforts.